Quiz: Role of Long Non-Coding RNAs in Ovarian Cancer

Article

How much do you know about the role of long non-coding RNAs in ovarian cancer? Now is your chance to find out.

In our September ovarian cancer quiz, you’ll be able to test your knowledge of the role long non-coding RNAs play in this disease. Here’s your first question:

1. In ovarian and other gynecologic cancers, long non-coding RNAs (lncRNAs) are key players in:

A. Cell proliferation

B. Invasion

C. Metastasis

D. All of the above


Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content
Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

Chris Ryan
June 4th 2025
Article

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer

Dostarlimab/Chemo, Maintenance Niraparib Show Modest Improvements in Ovarian Cancer

Tim Cortese
June 2nd 2025
Article

The median PFS with dostarlimab plus niraparib was 20.6 months vs 19.2 months with niraparib alone in patients with treatment-naive advanced ovarian cancer.

Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 17th 2018
Podcast

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.

FDA Grants Accelerated Approval to Avutometinib/Defactinib in KRAS+ LGSOC

Roman Fabbricatore
May 8th 2025
Article

Findings from the phase 2 RAMP 201 trial support the FDA approval of avutometinib plus defactinib in low-grade serous ovarian cancer.

The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers

Russ Conroy
April 30th 2025
Article

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.